Bionano Laboratories Sees 47% Increase in Medicare Payment for OGM Blood Cancer Test
ByAinvest
Wednesday, Dec 3, 2025 8:06 am ET1min read
BNGO--
Bionano Laboratories, a subsidiary of Bionano Genomics, has announced that the Centers for Medicare & Medicaid Services (CMS) has increased the payment for the Category I CPT code 81195 for optical genome mapping (OGM) in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematologic malignancies. The payment will increase by 47%, from $1263.53 to $1853.22, effective January 1, 2026. This increase reflects a request for reconsideration and crosswalk to a different code with a higher payment rate.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet